Home PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia
 

Keywords :   


PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia

2015-11-03 03:42:29| drugdiscoveryonline Home Page

PixarBio Corporation recently announced that it has filed an application with the US FDA Office of Orphan Products Development, for orphan drug status of our NeuroRelease TN (NR-TN) drug candidate for the treatment of Trigeminal Neuralgia (TN)

Tags: corporation drug submission announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
07.11Lawsuit over FDA's regulatory approval process for carbadox dismissed
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Tropical Depression Fourteen-E Graphics
More »